%0 Journal Article
%A Mecklenbrauck, Rabea
%A Villaverde Ramiro, Angela
%A Sträng, Eric
%A Gabdoulline, Razif
%A Martinez Elicegui, Javier
%A Sobas, Marta
%A Pleyer, Lisa
%A Turki, Amin
%A Voso, Maria Teresa
%A Benner, Axel
%A Hernández-Sánchez, Alberto
%A Tettero, Jesse M
%A Tur Gimenez, Laura
%A Metzeler, Klaus H
%A Oñate, Guadalupe
%A Lehmann, Sören
%A Huntly, Brian Jp
%A Thomas, Ian
%A Thol, Felicitas R
%A Heidel, Florian H
%A Valk, Peter Jm
%A Döhner, Konstanze
%A Haferlach, Torsten
%A Mills, Kenneth I
%A Döhner, Hartmut
%A Castellani, Gastone
%A Ossenkoppele, Gert J
%A Hernández-Rivas, Jesus María
%A Bullinger, Lars
%A Heuser, Michael
%T Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.
%J Leukemia
%V nn
%@ 0887-6924
%C London
%I Springer Nature
%M DKFZ-2026-00316
%P nn
%D 2026
%Z epub
%X The inclusion of nine myelodysplasia-related gene (MRG) mutations (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) as adverse risk factors in the ELN risk classification has reshaped classification in acute myeloid leukemia (AML). AML with FLT3-ITD mutations and co-occurring MRG alterations is now classified to the ELN adverse risk group although supporting evidence remains limited. Among 4,078 patients with AML with available molecular information included in the HARMONY platform, 862 harbored FLT3-ITD mutations and underwent intensive chemotherapy. Of these, 171 (20
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41663622
%R 10.1038/s41375-026-02874-w
%U https://inrepo02.dkfz.de/record/309803